a, a N Clinical Trials

A listing of a, a N clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1863 clinical trials
Draft-Version-001-Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases

Draft-Version-001- This study is a single center, open label exploratory clinical trial aimed at evaluating the safety and efficacy of universal CD19 CAR-T therapy in subjects with autoimmune diseases.

  • 0 views
  • 30 May, 2025
1 march 4  

The minimum acceptable dose for infusion is 1 x 10xE7 CART19 cells. Subjects originally treated under Stage 1 will receive a single infusion, if sufficient CART19 product remains. For patients from Stage 1 who do not have a sufficient dose remaining, subjects will be remanufactured under Stage 2 conditions and …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Compared with non-small-cell lung cancer (NSCLC) SCLC has a unique natural history with a shorter doubling time, higher growth fraction, earlier development of widespread metastases, and uniform initial response to chemo- or radiotherapy.

corticosteroid therapy
tuberculosis
systemic therapy
metastasis
pd-l1
  • 0 views
  • 19 Feb, 2024
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of APG-1387 in combination with toripalimab. A phase II study of 3 cohorts will be included.

colorectal cancer
neuropathy
metastasis
cancer
EGFR
  • 0 views
  • 19 Feb, 2024
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

ras-gef
BRAF
measurable disease
metastasis
gilbert's syndrome
  • 0 views
  • 19 Feb, 2024
Caterpillar Arterial Embolization Device Post-Market Study

The primary objective of this study is to evaluate the performance and safety of the Caterpillar Arterial Embolization Device when used for arterial embolization in the peripheral vasculature in a real world, on-label application.

  • 0 views
  • 19 Feb, 2024
Neoadjuvant RCT Versus CT for Patients With Locally Advanced Potentially Resectable Adenocarcinoma of the GEJ

This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing neoadjuvant radiochemotherapy with FLOT versus FLOT chemotherapy alone fr patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ)

adenocarcinoma
tubal occlusion
hormonal contraception
flot
leucovorin
  • 0 views
  • 19 Feb, 2024
Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

This study is a multicenter, single-arm, open, phase clinical study to evaluate the safety and efficacy of Toripalimab(JS001) monoclonal injection after chemotherapy in combination with Endostar for Locally Advanced or Metastatic Mucosal Melanoma.

maintenance treatment
mucosal melanoma
toripalimab
oral contraceptives
melanoma
  • 0 views
  • 19 Feb, 2024
Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

This is a prospective, open-label, randomized, two-arm clinical trial conducted to evaluate the safety and efficacy of romiplostim in comparison with eltrombopag in the treatment of thrombocytopenia in patients with Wiskott-Aldrich syndrome

platelet count
eltrombopag
wiskott-aldrich syndrome
thrombocytopenia
romiplostim
  • 0 views
  • 19 Feb, 2024
Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers

This is a Phase 1, single-dose, open-label, randomized, three-period, three-way crossover study in which healthy adult participants will receive three separate single-dose administrations of ASTX660 capsules under three different conditions.

systolic blood pressure
tubal ligation
oophorectomy
body mass index
hysterectomy
  • 0 views
  • 19 Feb, 2024